drugset / Trial / NCT00634569

Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects

NCT00634569

Phase 4 Completed 24 enrolled Grifols, S.A.
NaSingle-groupOpen-labelTreatment

Summary

This is a multi-center, open-label study to assess the efficacy and safety of Flebogamma 5% DIF in the pediatric population.

Timeline

Start
2008-05
Primary completion
2011-03
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic Intravenous